$BDPT
BIOADAPTIVES, INC.

2024 Q2 Form 10-Q Financial Statement

#000164033424000843 Filed on May 17, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $675.00 $11.99K
YoY Change -71.14% 255.27%
Cost Of Revenue $246.00 $8.393K
YoY Change -71.02% 501.22%
Gross Profit -$429.00 $3.601K
YoY Change -128.79% 81.87%
Gross Profit Margin -63.56% 30.02%
Selling, General & Admin $54.06K $51.49K
YoY Change -4.76% 153.77%
% of Gross Profit 1429.88%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $1.940K
YoY Change -100.0% 189.55%
% of Gross Profit 53.87%
Operating Expenses $93.41K $53.43K
YoY Change 62.62% 154.99%
Operating Profit -$92.98K -$49.83K
YoY Change 66.18% 162.62%
Interest Expense $17.97K $54.62K
YoY Change -65.61% 6.96%
% of Operating Profit
Other Income/Expense, Net -$90.04K -$256.9K
YoY Change 2.35% -4.23%
Pretax Income -$183.0K -$306.7K
YoY Change 27.17% 6.8%
Income Tax
% Of Pretax Income
Net Earnings -$183.0K -$306.7K
YoY Change 27.17% 6.8%
Net Earnings / Revenue -27113.63% -2557.17%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 1.175B shares 972.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.00 $19.60K
YoY Change -99.4% 227.76%
Cash & Equivalents $235.00 $19.60K
Short-Term Investments
Other Short-Term Assets $2.500K $2.500K
YoY Change
Inventory $6.000K $18.57K
Prepaid Expenses $0.00 $0.00
Receivables
Other Receivables
Total Short-Term Assets $8.735K $40.67K
YoY Change -81.27% 279.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $18.00K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $18.00K
YoY Change -100.0% 675.86%
TOTAL ASSETS
Total Short-Term Assets $8.735K $40.67K
Total Long-Term Assets $0.00 $18.00K
Total Assets $8.735K $58.67K
YoY Change -81.9% 349.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.280K $3.280K
YoY Change 135.29% 99.51%
Accrued Expenses $152.8K $146.0K
YoY Change 10671.46% 14223.16%
Deferred Revenue
YoY Change
Short-Term Debt $349.8K $320.8K
YoY Change -7.23% -10.3%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.930M $1.857M
YoY Change 11.79% 12.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.930M $1.857M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.930M $1.857M
YoY Change 11.79% 12.95%
SHAREHOLDERS EQUITY
Retained Earnings -$8.754M -$8.571M
YoY Change 9.66% 9.34%
Common Stock $123.2K $115.5K
YoY Change 113.67% 199.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.922M -$1.798M
YoY Change
Total Liabilities & Shareholders Equity $8.735K $58.67K
YoY Change -81.9% 349.93%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$183.0K -$306.7K
YoY Change 27.17% 6.8%
Depreciation, Depletion And Amortization $0.00 $1.940K
YoY Change -100.0% 189.55%
Cash From Operating Activities -$51.46K -$41.18K
YoY Change -9.51% 111.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.10K
YoY Change -64.74%
NET CHANGE
Cash From Operating Activities -51.46K -$41.18K
Cash From Investing Activities
Cash From Financing Activities 32.10K
Net Change In Cash -19.36K -$41.18K
YoY Change -156.66% 111.61%
FREE CASH FLOW
Cash From Operating Activities -$51.46K -$41.18K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 bdpt Total Convertible Notes Payable
TotalConvertibleNotesPayable
327790 usd
CY2024Q1 bdpt Common Stock Capital Shares Reserved For Future Issuance1
CommonStockCapitalSharesReservedForFutureIssuance1
10000 shares
CY2024Q1 bdpt Series B Preferred Stock Issued For License Fee Amount
SeriesBPreferredStockIssuedForLicenseFeeAmount
3000 usd
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001575142
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
895760225 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1154770641 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10000 shares
CY2023Q4 bdpt Common Stock Capital Shares Reserved For Future Issuance1
CommonStockCapitalSharesReservedForFutureIssuance1
10000 shares
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Entity File Number
EntityFileNumber
000-54949
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
BioAdaptives Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2592228
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2620 Regatta Drive
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89128
CY2024Q1 dei City Area Code
CityAreaCode
702
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
659-8829
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1174774530 shares
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19595 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60776 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
18572 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
15281 usd
CY2024Q1 us-gaap Security Deposit
SecurityDeposit
2500 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
2500 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
40667 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
88557 usd
CY2024Q1 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
18000 usd
CY2023Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
15441 usd
CY2024Q1 us-gaap Assets
Assets
58667 usd
CY2023Q4 us-gaap Assets
Assets
103998 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
450986 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
443579 usd
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1084801 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
977872 usd
CY2024Q1 bdpt Discount On Convertible Notes
DiscountOnConvertibleNotes
8387 usd
CY2023Q4 bdpt Discount On Convertible Notes
DiscountOnConvertibleNotes
52592 usd
CY2024Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
314103 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
321658 usd
CY2024Q1 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
6660 usd
CY2023Q4 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
7520 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1856550 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1750629 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1856550 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1750629 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1154770641 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
895760225 shares
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
115477 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
89576 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6656867 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6527428 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8570852 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8264145 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1797883 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1646631 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58667 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103998 usd
CY2024Q1 us-gaap Revenues
Revenues
11994 usd
CY2023Q1 us-gaap Revenues
Revenues
3376 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
8393 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1396 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
3601 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
1980 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31672 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12036 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
19820 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
8250 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1941 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
669 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
53433 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
20955 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-49832 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18975 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-10 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
54615 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
51063 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-202260 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-217139 usd
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-256875 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-268212 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-306707 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-287187 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-306707 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2024Q1 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
CY2023Q1 bdpt Basic And Diluted Earning Per Share
BasicAndDilutedEarningPerShare
-0.00
CY2024Q1 bdpt Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
980260314 shares
CY2023Q1 bdpt Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
267434761 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1646631 usd
CY2024Q1 bdpt Series A Preferred Stock Issued For License Fee Amount
SeriesAPreferredStockIssuedForLicenseFeeAmount
1500 usd
CY2024Q1 bdpt Series B Preferred Stock Issued For Settlement Of Debt Amount
SeriesBPreferredStockIssuedForSettlementOfDebtAmount
1500 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
149455 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-306707 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1797883 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1451501 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
108036 usd
CY2023Q1 bdpt Debts Forgiveness Related Party
DebtsForgivenessRelatedParty
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1630652 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
306707 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
287187 usd
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-202260 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-217139 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1941 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
669 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
44205 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
40233 usd
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-10 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3291 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4134 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10411 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5541 usd
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41181 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19461 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-41181 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19461 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60776 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25405 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19595 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5944 usd
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
0 usd
CY2023Q1 bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
35000 usd
CY2024Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
149455 usd
CY2023Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
108036 usd
CY2024Q1 bdpt Series A Preferred Stock Issued For License Fee
SeriesAPreferredStockIssuedForLicenseFee
1500 usd
CY2023Q1 bdpt Series A Preferred Stock Issued For License Fee
SeriesAPreferredStockIssuedForLicenseFee
0 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
7875 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
7125 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
0 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18000 usd

Files In Submission

Name View Source Status
bdpt-20240331_cal.xml Edgar Link unprocessable
0001640334-24-000843-index-headers.html Edgar Link pending
0001640334-24-000843-index.html Edgar Link pending
0001640334-24-000843.txt Edgar Link pending
0001640334-24-000843-xbrl.zip Edgar Link pending
bdpt-20240331.xsd Edgar Link pending
bdpt_10q.htm Edgar Link pending
bdpt_10qimg3.jpg Edgar Link pending
bdpt_ex311.htm Edgar Link pending
bdpt_ex312.htm Edgar Link pending
bdpt_ex321.htm Edgar Link pending
bdpt_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
bdpt-20240331_def.xml Edgar Link unprocessable
bdpt-20240331_lab.xml Edgar Link unprocessable
bdpt-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bdpt_10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending